Index

AAA, see abdominal aortic aneurysms abdominal aortic aneurysms (AAA) 88 abridged evaluation 409, 441, 545, 553, 554, 557 acceptable risks 285 ACCSQ, see ASEAN Consultative Committee on Standards and Quality active implantable medical devices (AIMD) 249, 259, 264–266, 268, 269, 271, 272, 274, 277, 279, 289, 292, 299, 365, 368, 369 ADR, see adverse drug reaction advanced therapy medicinal products (ATMP) 309 adverse drug reaction (ADR) 418, 460 adverse events 32, 99, 120–124, 229, 323, 333, 338, 354, 379, 383, 391, 398, 399, 446, 471, 472, 533, 543, 561, 562, 574 adverse events/incidents, reportable 354, 409, 410 adverse medical device reactions 125 advertisements 101, 403, 412, 434, 529, 535, 566, 567, 579 Advertising Standards Authority	AEC, see ASEAN Economic Community AHC, see APEC Harmonization Center AHWP, see Asian Harmonization Working Party AIMD, see active implantable medical devices AMDC, see ASEAN Medical Device Committee AMDD, see ASEAN Agreement on Medical Device Directive AMDD medical device classification 590 ancillary medicinal substance 260, 300, 305–309 antibiotics 302, 303, 306 APEC, see Asia-Pacific Economic Cooperation APEC Regulatory Harmonization Steering Committee (RHSC) 202, 578 ARGMD, see Australian Regulatory Guidelines for Medical Devices ARPA, see Asia Regulatory Professional Association ARTG, see Australian Register of Therapeutic Goods ASAS, see Advertising Standards Authority of Singapore
	•

- ASEAN, see Association of Australian Medical Device Southeast Asian Nations Regulations 361, 362, 364, 366, 368, 370, 372, 374, 376 ASEAN Agreement on Medical Australian Register of Device Directive (AMDD) Therapeutic Goods (ARTG) 582, 589, 590, 592, 594 117, 366 ASEAN Consultative Committee Australian Regulatory Guidelines on Standards and Quality for Medical Devices (ACCSQ) 438, 535 (ARGMD) 363-365, 367, **ASEAN Economic Community** 368, 372, 373 (AEC) 438 authorized representative 162, ASEAN Medical Device 266, 267, 280, 289, 290, Directive (AMDD) 582 294, 343-347, 349-351, Asian Harmonization Working 353, 356, 518, 519 Party (AHWP) 66, 339, 535, 578, 592 Asia-Pacific, regulatory affairs for medical device clinical bandages 240, 335, 405, 548, trials in 108, 110, 112, 550, 582 114, 116, 118, 120, 122, 124, 126 Asia-Pacific Economic Cooperation (APEC) 4, 202 Asia Regulatory Professional Association (ARPA) 2, 43, 175, 401, 475, 513, 541.591 Association of Southeast Asian Nations (ASEAN) 4, 9, 535, 582 ATMP, see advanced therapy medicinal products
- biocompatibility 83, 232, 253, 283, 389 biological products 243, 245, 460, 467 biomaterial 84 biomedical device industry 82 biomedical devices 79, 80, 82, 84, 86, 88-90 blood 29, 57, 61, 63, 80, 88, 89, 130, 132, 134, 136, 137, 241, 259, 260, 269, 270, 280, 300, 307, 308, 323-325, 333, 368, 375, 415, 416, 418, 460, 461, ATMP, see advanced therapy 545, 547, 548, 554, 570, medicinal products 585, 586 Australia 88, 98, 101, 117, 158, bone cements 302, 303, 305, 342, 346, 356, 361–363, 416 366, 367, 369-371, 374, borderline products 260, 300 376, 402, 408, 578, 592, Brazil medical device registration 596, 597 process 324 Australian Declaration of **British Standards Institution** Conformity 367, 369, 375 (BSI) 265

BSI, see British Standards	379, 382, 383, 406, 407,
Institution	416, 420, 425, 435, 440,
	441, 463–465, 467,
	547-553, 559, 560, 574,
	582, 584, 585, 590, 592,
CAGR, see compound annual	594–598,
growth rate	600
calibrators 136, 137, 269, 270,	clinical evaluation 40, 94, 99,
356, 373	100, 115, 261, 283, 285,
cardiovascular device 493, 574	287, 288, 292–296, 353,
cataracts 81, 86, 87	375, 384–387, 390–392,
CE Declaration of conformity	410, 455, 463, 501, 558,
272, 273, 288	575
CE-marked products 432	clinical investigation 40, 100,
CE marking of active implantable	261, 262, 286, 353, 354,
medical devices 274	501
CE marking of medical devices	clinical trial 9, 21, 66, 88,
253, 273	107–118, 120–126, 366,
CFDA, see China Food and Drug	376, 389, 391–393, 411,
Administration	418, 420, 426, 429,
CGMPs, see current good	431–433, 435, 436, 563,
manufacturing practices	577, 578
China 2, 3, 9, 81, 96, 98, 103,	agreement 120, 124
115, 119, 120, 377–386,	application 119, 123, 124, 393
388–400, 475, 478, 480,	approval 123, 124, 393, 396,
491	397
China Food and Drug	certificate 564
Administration (CFDA)	exemption 118, 391
378–386, 391–394,	notification 118, 563, 564
397-400	pharmaceutical 9, 107-111,
China medical device market	114, 115, 117, 433, 436,
378	577
chlamydia 134–136, 270	protocol 109, 118, 119, 123,
classification 2, 3, 21, 22, 36–39,	392, 393
109, 110, 124, 129–150,	regulation 115, 121
222–225, 233, 234,	regulations 9, 111, 113-115,
240–244, 247, 260, 267,	117
269–271, 290, 292, 296,	requirements 379, 432
300, 302, 303, 319, 320,	Colombia medical device system
323, 325, 327, 329, 330,	329, 331
332, 334, 335, 346, 348,	combination products 69, 239,
364, 365, 367, 369, 372,	240, 242–247, 299, 300,

302-304, 306, 308, 309,	138-150, 225, 270, 329,
428, 440	335, 406, 495, 582, 590,
cross-labeled 240, 244	595
drug-device 395, 398	devices 57, 58, 64–66, 72–76,
drug-device 299, 300	79–84, 88–90, 95–99,
compound annual growth rate	101–103, 108–112,
(CAGR) 312, 414, 438,	115–125, 131–137,
478, 479, 484, 491	193–200, 217–238,
conformity 36, 38, 39, 159, 171,	249–251, 253–269,
172, 193, 198–200, 249,	277–279, 289–295, 299,
250, 254, 255, 260, 262,	300, 302–309, 313–323,
264–266, 270–276,	327–330, 333–335,
278–280, 283, 285–288,	340–346, 348, 349,
290–292, 299, 356,	351–357, 362–372,
366–369, 374, 375, 385,	374–376, 378–395,
388, 407, 408, 410, 420,	397-400, 402-411,
426, 427, 432, 435, 447,	414-418, 423-425,
453, 466, 468, 500, 516,	430-432, 435-441,
557, 558, 576, 583, 595,	443-445, 459, 460,
597, 599	462-468, 471-473,
conformity assessment 265,	478-480, 482-485,
279, 374, 597	491-497, 514-517,
conformity assessment bodies	527-529, 532-538,
264, 356, 407-409, 516	542-545, 547-550,
contract sterilizers 450	552-557, 559-567,
control materials 136, 137, 269,	571-577, 582-590,
270, 356, 373	592-598
cosmetics 116, 124, 218, 220,	dental 258, 268, 319, 344, 404,
241, 333, 346, 381, 415,	484, 485, 487, 488, 532,
418-420, 435, 478, 479,	552, 574
527, 569, 572	diagnostic 86, 362, 416, 453
current good manufacturing	electrical surgical 484, 485
practices (CGMPs) 245	exempt 159, 225, 228, 269,
	349, 497
	higher-risk 37, 295
	highest-risk 223, 226
design validation 290, 453, 455	high-risk 53, 223, 234, 279,
developing countries 57–60, 62,	379, 393, 394, 466
64, 66, 194	implantable active drug
device classification 3, 36–39,	administration 269
124, 130–132, 134, 136,	imported 82, 120, 121, 123,
	-

238, 318, 321, 322, 328, 333, 341, 346, 349, 384–386, 390, 392, 394,	446, 460, 472, 473, 478, 479, 527–529, 545, 572 imported 120, 328, 414, 416,
397, 398, 411, 414, 416, 418, 424, 426, 430, 437,	418, 424, 426, 430, 572 investigational 109, 120
438, 441, 466, 480, 484,	mvestigational 107, 120
499, 525, 542, 544, 564,	
572, 576, 582, 592, 595, 596, 599, 600	DOOMEGIA D
invasive 88, 131, 143, 145, 147,	ECOTECH, see Economic and Technical Cooperation
267, 290 low-moderate-risk 223, 279,	EEA, see European Economic Area
548	EFTA, see European Free Trade
radiation-emitting 218, 219, 227, 341, 417, 525, 538	Association
radiation-emitting electronic 219, 341	e-labeling 101–103, 105 electrical stimulation 184,
single-use 278, 291, 345, 355, 548, 587, 596	186–188, 190 EMA, see European Medicines
diagnostic devices 86, 101, 132, 135, 227, 265, 266, 362,	Agency EU Classification of Medical Devices 267
416, 453, 536, 573 in vitro 101, 132, 135, 227,	Eudamed 53, 295
362, 416, 536, 572, 573	European Commission 52, 53, 74, 102, 250, 289, 300, 303
documentation 10, 20, 21, 23, 29, 36, 38–40, 123, 160,	European Economic Area (EEA)
163, 178–180, 202, 206,	250, 251 European Free Trade Association
213, 235, 250, 260, 262, 271–276, 278–283, 290,	(EFTA) 250, 251
296, 308, 320, 322, 325,	European Union (EU) 3, 52, 53,
327, 330, 332, 335, 337,	55, 69, 70, 74, 75, 96–98, 101, 102, 104, 136, 158,
347, 368, 369, 374, 375, 398, 409, 410, 428, 453,	175, 177, 178, 215,
465, 498, 499, 502, 538,	250–256, 258, 260,
605	262–264, 266, 268, 270, 272, 274–276, 278, 280,
drug-eluting stents 240, 416, 417, 432, 434, 576	282, 284, 286, 288,
drugs 53, 57, 59, 109, 116, 120,	290–292, 294, 296, 300,
132, 135, 220, 221, 240, 242, 243, 245, 260, 313,	302–304, 306, 308, 314–316, 329, 382, 402,
328, 404, 405, 414–416, 418–425, 428, 430–436,	408, 410, 492, 495, 553, 575, 578, 592, 596, 597

Failure Mode and Effect Analysis good quality practice (GQP) 463, 469 (FMEA) 175 FES. see functional electrical good review practice (GRevP) stimulation 202, 203, 214, 578 Field Safety Corrective Actions good submission practice 201, 202, 204, 206, 208, 210, (FSCA) 288 FMEA, see Failure Mode and Effect 212, 214 Analysis good submission practice FSCA, see Field Safety Corrective (GSubP) 202, 203, 214, 572 Actions GQP, see good quality practice functional electrical stimulation GRevP, see good review practice (FES) 184 GSubP, see good submission practice GUDID, see Global Unique Device Identification Database GCP, see good clinical practices GHO, see Global Health Observatory GHTF, see Global Harmonization Health Canada 104, 132, 315, Task Force GHTF classification 267 health technology assessment GHTF guidelines 419, 430, 431, 435 HIV infection 63, 65, 269, 586 GIP, see good importation HIV treatment 61 practice Hong Kong 98, 120, 175, Global Harmonization Task 401-412 Force (GHTF) 8, 9, 55, 66, 95, 130, 206, 250, 342, 356, 381, 402, 414, 459, 464, 535, 592 IEC, see International Global Unique Device Electrotechnical Identification Database Commission IMDRF, see International Medical (GUDID) 230 GMP, see good manufacturing Devices Regulators' Forum practices implantable devices 344, 345, good clinical practices (GCP) 503, 554 active 344, 345, 554 235, 501 good distribution practice 313, India 9, 116, 120, 129, 413–418, 414, 477, 478, 480, 572, 575 420-426, 428, 430-436, good manufacturing practices (GMPs) 225, 228, 245, 320, Indonesia 437-442, 444-446,

448, 450, 452, 454, 456, 458

431, 538, 577, 605

Indonesian medical device	JMDN, see Japanese Medical
market 438	Device Nomenclature
innovation 8, 38, 58, 65, 114,	KCL, see Korea Conformity
194, 219, 230, 233, 236,	Laboratories
397, 398, 488, 542, 544	KEETI, see Korea Electric and
intellectual property 542	Electric Testing Institute
International Electrotechnical	KFDA, see Korean Food and Drug
Commission (IEC) 105,	Administration
177, 193–199, 255, 325,	KGMP, see Korean Good
380, 447, 500	Manufacturing Practice
International Medical Devices	Kingdom of Saudi Arabia (KSA)
Regulators' Forum (IMDRF)	339, 342–348, 351–357
8, 9, 66, 205, 250	Korea 96, 98, 103, 123, 475–478,
invasive devices 88, 131, 139,	480, 482, 484, 486, 488,
141, 143, 145, 147, 267,	490–494, 496, 498–504,
290	506, 508, 510, 511
irradiating apparatus 402, 404,	Korea Conformity Laboratories
405	(KCL) 500
ISO 9001 154, 155, 158, 172,	Korea Electric and Electric
598, 599	Testing Institute (KEETI)
ISO 13485 153–156, 158–163,	500
165, 166, 170, 172, 173,	Korean Food and Drug
228, 253, 279, 284, 285,	Administration (KFDA)
296, 380, 409, 420, 428,	123
432, 447, 452, 468, 500,	Korean Good Manufacturing
556, 558, 563, 576, 598, 599	Practice (KGMP) 493, 494
ISO 14971 3, 165, 175–178, 180,	Korean Testing Lab (KTL) 500
182, 184, 186–188, 190,	KSA, see Kingdom of Saudi Arabia
197, 199, 283, 285, 321,	KTL, see Korean Testing Lab
326, 330, 374, 380	
	l-b-l: 27 20 02 105 112
1 01 02 114 115 120 224	labeling 37, 39, 93–105, 112,
Japan 81, 82, 114, 115, 129, 334,	225–228, 232, 262, 265,
342, 346, 356, 402, 408,	267, 277, 278, 283, 286,
459–464, 466–470, 472,	287, 290, 291, 293, 296,
474, 475, 480, 491, 556,	320, 321, 325, 326, 333,
578, 592, 596, 597	335, 343, 346, 351–354,
Japanese Medical Device	357, 410, 415, 430, 431,
Nomenclature (JMDN) 464	435, 443, 446, 450, 455,
JFDA, see Jordan Food and Drug	457, 466, 468, 492, 498,
Administration	499, 517, 520, 526, 534,

535, 538, 551, 558, 560, 564, 576, 587, 592, 598, 605 electronic 95, 97, 101–103, 208, 347, 352, 499 elements of 94, 95, 97 Latin America 66, 215, 311–313, 315–317 left ventricular assist device	medical device risk analysis 175 medical devices 7–9, 57, 58, 64–66, 72–76, 79–82, 95–99, 101–103, 108, 109, 116–125, 133–135, 153, 154, 193–200, 218–223, 225–231, 235–238, 249–251, 255–261, 263–269, 289, 290, 299,
(LVAD) 104	300, 313–317, 319–323,
license to operate (LTO) 525,	328-330, 340-346,
533, 534, 537	354–357, 362–372,
local responsible person (LRP)	374–376, 378–395,
407	402–409, 414–417, 420,
LRP, see local responsible person LTO, see license to operate	430–432, 437–441,
LVAD, see left ventricular assist	443–445, 459, 460, 462–468, 471–473,
device	482–485, 491–494,
ucvicc	514–517, 527–529,
	534–538, 542–545,
	547–550, 552–557,
magnetic resonance imaging	560–567, 571–577,
(MRI) 80, 482	582-587, 590, 592-598
MAH, see marketing authorization	active 8, 74, 131-133, 140,
holder	141, 249, 253, 256, 257,
Malaysia 116, 121, 513, 514,	259, 264–269, 274, 277,
516, 518, 520	289, 290, 292, 295, 299,
marketing authorization holder	308, 313, 334, 344, 345,
(MAH) 464–467, 469, 471,	365, 388, 443, 554
472	advertisement of 567
MDACS, see Medical Device	affordable 57–62, 64, 66, 193,
Administrative Control	194, 542
System MDCO, see Medical Device	commercialization of 315, 328, 544
Control Office	complex 8, 19, 58, 75, 84, 95,
Medical Device Administrative	109, 198, 323, 549
Control System (MDACS)	controlled 81, 96, 109, 169,
98, 403, 406, 601	307, 308, 398, 465–467,
Medical Device Control Office	572, 590
(MDCO) 120, 403, 404	diagnostics 8, 9, 47, 57, 59, 60,
medical device registration,	62, 69, 250, 259, 269, 320,
voluntary 543	423, 484, 485, 489, 493, 594

disinfection of 355, 440, 514, PAHO, see Pan American Health 536, 547, 584 Organization implantable 80, 104, 131, 132, Pan American Health 249, 253, 259, 264-269, Organization (PAHO) 316, 274, 277, 289, 292, 299, 317 334, 344, 345, 365, 406, PDCA, see Plan-Do-Check-Act 425, 548, 552, 554 pharmaceuticals 47, 111, 258, 411, 414, 432, 433, 436, reclassification of 571 refurbished 356, 357, 520 459, 460, 463 Pharmaceuticals and Medical unapproved 118, 125, 376 Devices Agency (PMDA) unregistered 122, 123, 564, (Japan) 460, 462, 465-467, 565 469, 471-473 medicinal product evaluation Philippines 523-530, 532, 309 medicinal products 130, 260, 534–536, 538–540 299, 301, 303, 304, 307, phthalates 291–293 Plan-Do-Check-Act (PDCA) 157, 309, 320, 548, 553, 559, 161 560 plastic blood bags 323, 325 medicinal substances 299, 305, PMDA, see Pharmaceuticals and 308, 309, 374, 375, 410 Medical Devices Agency medicines 70, 72, 98, 116, 119, (Japan) 121, 214, 263, 264, 291, PMS, see post-marketing 293, 299, 303, 306, 307, surveillance 374, 375, 406, 433 PMSR, see post-marketing safety medtech regulatory journalist reporting 51-55 post-marketing safety reporting microbiology devices 135, 574 (PMSR) 245 post-marketing surveillance (PMS) 100, 164, 171, 261, 283, 288, 295, 328, 407, new drugs 57, 418, 432 408, 420, 431, 444, 516, non-invasive devices 139, 141 560, 561, 571, 599 non-significant risk 235 preclinical trials 110, 111 predicate device 37, 231–234 premarket application 492, 496 premarket approval 222, 224, ophthalmic devices 86, 574 226, 232–235, 407, 466, Organisation for Professionals 492, 571, 597 in Regulatory Affairs, The premarket notification 223, 225, (TOPRA) 69-71, 73, 74, 76 231, 233

premarket submission 223, 236 product recall 411, 533, 539, 563 product registration 2, 20, 36, 38, 40, 112, 124, 202–204, 211, 214, 315–317, 320, 321, 325, 326, 378, 383,	343, 365, 444, 460, 513, 515, 516, 524, 542, 548, 561, 571, 579, 581, 583, 584, 589
385, 386, 408, 409, 411, 427, 429–431, 433, 520, 526, 534, 537, 538, 544, 545, 549, 552, 553, 555–557, 559, 560, 563, 588, 597–599, 607	QMS, <i>see</i> quality management system QMS inspections 468, 469 quality assurance 271–273, 275, 276, 390, 453, 467 quality control 197, 202, 282,
product registration approvals in GHTF countries 411 products complex 75, 502 cross-labeled 240, 244 diagnostic 59, 86, 114, 123, 135, 227, 253, 257, 259, 261, 264, 266, 274, 301, 320, 345, 364, 388, 416, 440, 468, 534, 547, 548, 572, 573, 578, 584, 586 drug-delivery 260, 300, 304 latex 227, 582	298, 373, 389, 394, 431, 468, 469, 472, 575 quality management system (QMS) 36, 38, 39, 153–157, 159, 162–165, 168, 170–174, 178, 228, 273, 279, 281, 283, 284, 394, 409, 432, 450, 452, 462, 465, 468, 469, 494, 500, 556, 558, 562, 563
pharmaceutical 54, 69, 70, 79, 107–109, 114, 115, 150, 402, 460, 461, 464, 492, 535, 571, 572, 576 premarket 426 radiation-emitting 218, 219, 227, 417, 525, 538 reagent 136, 221, 364, 388, 534, 536, 538, 546, 572, 583, 586 tobacco 218, 333 in vitro diagnostic 123, 534 PSA, see prostate-specific antigen public health 59, 60, 62, 63, 65, 111, 122, 134, 217, 236, 237, 241, 243, 316, 340,	RAPS, see Regulatory Affairs Professionals Society recall 294, 323, 399, 407, 411, 431, 472, 517, 533, 539, 562, 563 regulatory affairs professionals 47-49, 108, 113, 114, 125, 311 regulatory compliance 44, 158, 159, 164, 180, 290 regulatory harmonization 202, 578 request for designation (RFD) 243, 244, 246 residual risk 4, 176, 182, 183, 190, 285

RFDs, see request for designation RHSC, see APEC Regulatory Harmonization Steering Committee risk analysis 64, 99, 175, 176, 181, 182, 285, 289, 384, 440, 466, 558 risk-based classification 234, 292, 425, 435, 465 risk control 4, 176, 182, 189, 285, 456 risk evaluation 176, 182, 188, 285 risk management 2, 4, 38, 94, 99, 102, 155, 165, 166, 175-180, 183, 185, 187, 189, 190, 197, 199, 200, 283, 285, 286, 291, 293-295, 298, 321, 326, 330, 374, 375, 456, 526, 547, 575 Saudi Arabia 215, 340, 342, 344, 346, 348, 350, 352, 354, 356 SCAP, see Singapore Code of **Advertising Practice** SCI, see Science Citation Index

Science Citation Index (SCI) 501 serious injury 122, 229, 561, 562 Singapore 541–546, 548, 550, 552-556, 558, 560-564 Singapore Code of Advertising Practice (SCAP) 566, 567 Singapore Health Sciences Authority 98, 137 Singapore Medical Device Register 558, 559

sterile products 416, 448, 450, 526, 586 sterilization validation 282, 450, 451, 556 stimulation electrodes 185, 187, 188 storage conditions 169, 282, 321, 326, 452, 498 surgical procedure 85, 240 syringes 2, 3, 99, 240, 259, 300, 304, 415–417, 488, 582

Taiwan 114, 124, 158, 569-574, 576, 578-580 medical device market 570 Taiwan Food and Drug Administration (TFDA) 116, 124, 569 technical documentation 36, 38, 39, 206, 250, 260, 262, 274, 278–283, 290, 296, 325, 330, 374, 375, 410, 465, 498, 499

TFDA, see Taiwan Food and Drug Administration Thai FDA 125, 583, 584, 588 Thailand 116, 125, 581-584, 586-590 therapeutic products 45 tissues 132, 267, 333, 410, 446, 447, 586 TOPRA, see The Organisation for Professionals in Regulatory **Affairs** transmissible spongiform encephalopathies (TSEs) 374, 375

trials, pivotal 110 TSEs, see transmissible spongiform encephalopathies UDI, see unique device identification unique device identification (UDI) 95, 96, 229, 230, 295 unique device identifier 95, 230, 250 unique product identifier 372 United States 63, 82, 96, 104, 115, 177, 215, 218, 220, 222, 224, 226, 228, 230-232, 234, 236-242, 244, 246, 251, 312, 313, 316, 317, 334 United States Food and Drug Administration (USFDA) 217, 417, 426, 433, 434 United States Medical Device Regulatory Framework 217, 218, 220, 222, 224,

226, 228, 230, 232, 234, 236, 238 USFDA, see United States Food and Drug Administration Vietnam 591–594, 596–600 WAND, see web assisted notification of devices Web Assisted Notification of Devices (WAND) 121 World Health Organization 57, 60, 202, 317, 557

"This is an excellent and comprehensive book for researchers in medical devices, for students who want to get early exposure to safety and efficacy issues, and for marketing/sales personnel who need to know the various institutions that approve regulatory matters for market accessibility."

Prof. Swee-Hin Teoh Nanyang Technology University, Singapore

"While much has been written about US and European medical device regulations, the Asian regulatory picture has remained clouded for most people. This book is an excellent reference for understanding what is required to bring medical devices to market under the many different regulatory systems in this important region. It is a useful tool as companies and innovators are increasingly looking to Asia as not only a new market for existing products but a launching pad for new technologies."

Mark Holmes Terumo BCT, Inc., USA

"This is a very interesting book for biomedical engineering students and medical engineers and an important reference for regulatory affairs professionals."

Dr. Kwok-kwan ChanHospital Authority, Hong Kong
Chairman in Biomedical Division (2012–13), Hong Kong Institution of Engineers

This handbook covers medical device regulatory systems in different countries, ISO standards for medical devices, clinical trial and regulatory requirements, and documentation for application. It is the first to cover the medical device regulatory affairs in Asia. Experts from influential international regulatory bodies, including the US Food and Drug Administration (FDA), UK Medicines and Healthcare Products Regulatory Agency, Japan Pharmaceuticals and Medical Devices Agency, Saudi Food and Drug Authority (SFDA), Korea Testing Laboratory, Taiwan FDA, World Health Organization, Asian Harmonization Working Party, Regulatory Affairs Professionals Society, and British Standards Institution, have contributed to the book. Government bodies, the medical device industry, and academics and students will find the book immensely useful for understanding the global regulatory environment and in their research and development projects.



Jack Wong is the founder of the Asia Regulatory Professional Association (ARPA). He has more than 20 years of experience in regulatory affairs, clinical trials, and pharmacovigilance in Asia and possesses good knowledge in the field of medical devices, pharmaceuticals, and nutritional, consumer healthcare, and biological products. Prof. Wong developed the First Asia Regulatory Affairs Certificate course in 2007 and has been teaching at more than 10 universities.



Raymond K. Y. Tong is professor and founding chair in the Department of Biomedical Engineering, the Chinese University of Hong Kong; chair of the Hong Kong Local Responsible Person Panel and the ARPA-Hong Kong Academy; and honorary advisor of the Hong Kong Medical and Healthcare Device Industries Association. He has developed new regulatory courses at the Chinese University of Hong Kong on "Medical Device Regulatory Affairs and Intellectual Property" and "Global Medical

Device Regulatory Affairs." Prof. Tong's research interests include rehabilitation robotics, functional electrical stimulation, magnetic resonance imaging, electroencephalography, and stroke rat model. His inventions have received the Ten Outstanding Young Persons in Hong Kong Award (2013), HKIE Innovation Award for Young Members (2008), five gold awards in international invention exhibitions in China (2004), Belgium (2007), Germany (2010), and Switzerland (2012, 2016), Hong Kong ICT Award (2012, 2017), and Hong Kong Award for Industry (2003).



